Evolution of the Average Target: Valneva SE

Evolution of the Average Target - Valneva SE

Evolution of the Target Price: Valneva SE

Evolution of the Target Price - Valneva SE

Changes in Analyst Recommendations: Valneva SE

fab7d15da01854.bQCavq7w1DkqSSB6phpZP8pw7jJyrqLPGqN6v4idVGY.JDL009bI7FsTCEYC_1cvUYIg2XRCy_f9fsACyd_ILFZASN2Tz8mSQUk4eQ~6855b98e39d61cc1f1f8acf53a82d388
08-11 TD Cowen Initiates Valneva at Buy Rating, With $12 Price Target MT
05-13 French Analyst Ratings: Aramis and Valneva penalized following profit warnings Zonebourse
04-30 Schneider Electric, Capgemini, Societe Generale... stocks to watch today in Paris Zonebourse
04-22 Goldman Sachs Downgrades Valneva to Sell From Neutral, Adjusts Price Target to $4.90 From $7.50 MT
04-22 French Analyst Ratings: Thales, Vallourec and Valneva in the Spotlight Zonebourse
03-18 Valneva heads for fourth consecutive gain following annual results Zonebourse
01-20 Stifel Reiterates Buy Rating and Price Target on Valneva Zonebourse
01-06 Valneva, Biggest Gainer on SBF 120 and SRD at Close of Tuesday, January 6, 2026 Zonebourse
01-06 Valneva Surges on Positive Broker Comments Zonebourse
01-06 CAC 40 Lags Behind; Valneva in Demand Zonebourse
01-06 Valneva Posts Strongest Midday Gain on SBF 120, Tuesday, January 6, 2026 Zonebourse
01-06 Stock of the Day in Paris – Valneva Bolstered by Stifel Zonebourse
01-06 Stifel Raises Price Target for Valneva Zonebourse
01-06 Analysts' calls of the day: Bernstein favors Thales over BAE Systems and Dassault Aviation Zonebourse
11-20 Stifel Reiterates Buy Recommendation on Valneva Zonebourse
11-04 Valneva SE Announces Positive Results of Its Phase 1 Clinical Trial Investigating the Safety and Immunogenicity of VLA1601 CI
03/09/25 Valneva publishes positive data for its Lyme disease vaccine candidate, stock rises RE
26/08/25 Valneva: Stifel Adjusts Price Target Following FDA Suspension of Ixchiq License Zonebourse
26/08/25 Valneva: Stifel adjusts target price Zonebourse
12/08/25 Valneva: Oddo BHF confirms 'outperform' rating Zonebourse
14/07/25 Valneva Shares Surge After EMA Lifts Restriction on Chikungunya Vaccine RE
13/08/24 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
24/06/24 Valneva rises after Canadian approval for its chikungunya vaccine RE
05/02/24 Valneva: Oddo BHF confirms its recommendation on the stock Zonebourse
02/01/24 Valneva: Oddo BHF remains positive Zonebourse

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+160.72%
+45.94%
+27.74%
+8.21%
+20.68%
+21.12%
+37.56%
+8.25%
+40.97%
+77.27%
Average +44.85%
Weighted average by Cap. +30.11%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
2.378EUR
Average target price
6.200EUR
Spread / Average Target
+160.72%
High Price Target
12.00EUR
Spread / Highest target
+404.63%
Low Price Target
2.200EUR
Spread / Lowest Target
-7.49%

Analyst Consensus Detail

Analyst consensus - Valneva SE

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Valneva SE
Trader
Investor
Global
Quality
ESG MSCI
BBB
MarketScreener Ratings - Valneva SE
  1. Stock Market
  2. Stocks
  3. VLA Stock
  4. Consensus Valneva SE